Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors
暂无分享,去创建一个
[1] Jeremy G. Vinter,et al. Extended electron distributions applied to the molecular mechanics of some intermolecular interactions , 1994, J. Comput. Aided Mol. Des..
[2] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[3] A. N. Jain,et al. Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark. , 1994, Journal of medicinal chemistry.
[4] A. Brodie,et al. Aromatase inhibitors in the treatment of breast cancer , 1994, The Journal of Steroid Biochemistry and Molecular Biology.
[5] Pui-Kai Li,et al. Biochemical and pharmacological development of steroidal inhibitors of aromatase , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[6] Ian A. Wilson,et al. Molecular basis of crossreactivity and the limits of antibodyantigen complementarity , 1993, Nature.
[7] Yvonne C. Martin,et al. New strategies that improve the efficiency of the 3D design of bioactive molecules , 1993 .
[8] Mitsuteru Numazawa,et al. Synthesis of Androst‐5‐en‐7‐ones and Androsta‐3,5‐dien‐7‐ones and Their Related 7‐Deoxy Analogues as Conformational and Catalytic Probes for the Active Site of Aromatase. , 1994 .
[9] Mitsuteru Numazawa,et al. 6α,7 ga-Cyclopropane derivatives of androst-4-ene: A novel class of competitive aromatase inhibitors , 1991 .
[10] James J. P. Stewart,et al. MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..
[11] M Numazawa,et al. Synthesis of androst-5-en-7-ones and androsta-3,5-dien-7-ones and their related 7-deoxy analogs as conformational and catalytic probes for the active site of aromatase. , 1994, Journal of medicinal chemistry.
[12] Thompson Ea,et al. The Involvement of Human Placental Microsomal Cytochrome P-450 in Aromatization , 1974 .
[13] S. Neidle,et al. A detailed molecular model for human aromatase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[14] R. Hartmann,et al. Aromatase inhibitors. Syntheses and structure-activity studies of novel pyridyl-substituted indanones, indans, and tetralins. , 1994, Journal of medicinal chemistry.
[15] Y J Abul-Hajj,et al. Aromatase inhibition by 4-thiosubstituted-4-androstene-3,17-dione derivatives. , 1990, Journal of steroid biochemistry.
[16] P K Li,et al. Synthesis and biochemical studies of 7-substituted 4,6-androstadiene-3,17-diones as aromatase inhibitors. , 1990, Journal of medicinal chemistry.
[17] R. Brueggemeier,et al. Steroidal inhibitors as chemical probes of the active site of aromatase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[18] Opera Ti,et al. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results. , 1994 .
[19] D. Zhou,et al. Functional domains of aromatase cytochrome P450 inferred from comparative analyses of amino acid sequences and substantiated by site-directed mutagenesis experiments. , 1992, The Journal of biological chemistry.
[20] J. Topliss,et al. Chance correlations in structure-activity studies using multiple regression analysis , 1972 .
[21] D. E. Patterson,et al. Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .
[22] E. Simpson,et al. Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis. , 1993, Molecular endocrinology.
[23] K. Korzekwa,et al. Mutagenesis study at a postulated hydrophobic region near the active site of aromatase cytochrome P450. , 1994, The Journal of biological chemistry.
[24] J. Kellis,et al. Purification and characterization of human placental aromatase cytochrome P-450. , 1987, The Journal of biological chemistry.
[25] G. Cruciani,et al. Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .
[26] M Numazawa,et al. 19-Hydroxy-4-androsten-17-one: potential competitive inhibitor of estrogen biosynthesis. , 1989, Biochemical and biophysical research communications.
[27] N. Peet,et al. A-ring bridged steroids as potent inhibitors of aromatase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[28] T. Poulos,et al. High-resolution crystal structure of cytochrome P450cam. , 1987, Journal of molecular biology.
[29] B. Skagerberg,et al. Predictive ability of regression models. Part I: Standard deviation of prediction errors (SDEP) , 1992 .
[30] G R Marshall,et al. 3D-QSAR: a current perspective. , 1995, Trends in pharmacological sciences.
[31] Chris M. W. Ho,et al. De Novo Design: Ligand Construction and Prediction of Affinity , 1995 .
[32] William Francis Ganong,et al. Review of Medical Physiology , 1969 .
[33] R. D'Alessio,et al. 4-aminoandrostenedione derivatives: A novel class of irreversible aromatase inhibitors. Comparison with FCE 24304 and 4-hydroxyandrostenedione , 1990, The Journal of Steroid Biochemistry and Molecular Biology.
[34] Shiuan Chen,et al. Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala and their interactions with aromatase inhibitors , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[35] Paul Geladi,et al. Principal Component Analysis , 1987, Comprehensive Chemometrics.
[36] T. Poulos,et al. A site-directed mutagenesis study of human placental aromatase. , 1992, The Journal of biological chemistry.
[37] J P Burkhart,et al. Novel time-dependent inhibitors of human placental aromatase. , 1991, Journal of medicinal chemistry.
[38] Shiuan Chen,et al. Structure-function studies of human aromatase , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[39] Tudor I. Oprea,et al. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes. , 1994, Journal of medicinal chemistry.
[40] N. Peet,et al. Biological characterization of A-ring steroids , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[41] M Numazawa,et al. Synthesis and biochemical studies of 16- or 19-substituted androst-4-enes as aromatase inhibitors. , 1991, Journal of medicinal chemistry.
[42] Tudor I. Oprea,et al. Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules. , 1993, Journal of medicinal chemistry.
[43] M Numazawa,et al. 6-Alkyl- and 6-arylandrost-4-ene-3,17-diones as aromatase inhibitors. Synthesis and structure-activity relationships. , 1994, Journal of medicinal chemistry.
[44] A. Panzeri,et al. Novel aromatase and 5α-reductase inhibitors , 1994, The Journal of Steroid Biochemistry and Molecular Biology.
[45] T. Hassard,et al. Applied Linear Regression , 2005 .
[46] D. Pompon,et al. Structure-function studies of human aromatase by site-directed mutagenesis: kinetic properties of mutants Pro-308----Phe, Tyr-361----Phe, Tyr-361----Leu, and Phe-406----Arg. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[47] K. Appelt,et al. Crystal structures of HIV-1 protease-inhibitor complexes , 1993 .
[48] Evan R. Simpson,et al. Tissue-specific promoters regulate aromatase cytochrome P450 expression , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[49] P. Li,et al. 7-substituted 1,4,6-androstatriene-3,17-diones as enzyme-activated irreversible inhibitors of aromatase. , 1990, Journal of steroid biochemistry.
[50] G. Cruciani,et al. Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. , 1994, Journal of medicinal chemistry.
[51] C. Wermuth,et al. Trends in QSAR and Molecular Modelling 92 , 1993 .